Healthcare -
Drug Manufacturers - Specialty & Generic - NYSE - CA
$ 5.26
-1.31 %
$ 1.94 B
Market Cap
-40.46
P/E
1. INTRINSIC VALUE
Balance Sheet
Bausch Health Companies Inc.
| Current Assets | 5.77 B |
| Cash & Short-Term Investments | 1.18 B |
| Receivables | 2.14 B |
| Other Current Assets | 2.45 B |
| Non-Current Assets | 20.7 B |
| Long-Term Investments | 0 |
| PP&E | 1.78 B |
| Other Non-Current Assets | 19 B |
| Current Liabilities | 6.75 B |
| Accounts Payable | 656 M |
| Short-Term Debt | 2.67 B |
| Other Current Liabilities | 3.42 B |
| Non-Current Liabilities | 20.1 B |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 20.1 B |
EFFICIENCY
Earnings Waterfall
Bausch Health Companies Inc.
| Revenue | 9.52 B |
| Cost Of Revenue | 2.78 B |
| Gross Profit | 6.74 B |
| Operating Expenses | 5.3 B |
| Operating Income | 1.55 B |
| Other Expenses | 1.62 B |
| Net Income | -72 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bausch Health Companies Inc.
| Net Income | -72 M |
| Depreciation & Amortization | 1.27 B |
| Capital Expenditures | -337 M |
| Stock-Based Compensation | 150 M |
| Change in Working Capital | 7 M |
| Others | 34 M |
| Free Cash Flow | 1.26 B |
Wall Street Analysts Price Targets
Bausch Health Companies Inc.
Wall Street analysts predict an average 1-year price target for BHC of $9 , with forecasts ranging from
a
low of
$7 to a high of $11 .
BHC Lowest Price Target
Wall Street Target
7 USD
33.08%
BHC Average Price Target
Wall Street Target
9 USD
71.10%
BHC Highest Price Target
Wall Street Target
11 USD
109.13%
4. DIVIDEND
ANALYSIS
BHC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Bausch Health Companies Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
3.67 K USD 1
6-9 MONTHS
83 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity
One-eighth of the global population and one-fifth of U.S. adults suffer from mental health conditions, highlighting an urgent need for better psychiatric care. Bausch Health's Aplenzin shows promise for treatment-resistant depression (TRD), potentially offering better efficacy and tolerability compared to Wellbutrin, addressing a significant unmet medical need. Repositioning Aplenzin for TRD could unlock a $3 billion market opportunity, aiding Bausch Health's financial recovery and providing substantial clinical benefits.
seekingalpha.com
- 2 weeks ago
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS Symptoms Aren't Black and White: Living in the Gray, an authentic storytelling campaign that addresses the complexities of living with irritable bowel syndrome (IBS).
accessnewswire.com
- 2 weeks ago
Bausch + Lomb recalls some of its implantable eye lenses
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
reuters.com
- 3 weeks ago
Bausch + Lomb Recalls EnVista Intraocular Lenses
The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.
marketwatch.com
- 3 weeks ago
Bausch Health to Announce First Quarter Results on April 30
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
accessnewswire.com
- 3 weeks ago
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
benzinga.com
- 3 weeks ago
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
accessnewswire.com
- 3 weeks ago
Bausch Health Announces Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027 (collectively, the "BHC Notes") and (ii) 1375209 B.C. Ltd., the Company's indirect wholly-owned subsidiary ("HoldCo"), has delivered a conditional notice of redemption for all of its outstanding 9.000% Senior Secured Notes due 2028 (collectively with the BHC Notes, the "Notes").
accessnewswire.com
- 4 weeks ago
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B facility (the "New Term Loan Facility" and, together with the New Revolving Facility, the "New Senior Secured Credit Facilities") through its indirect wholly-owned subsidiary, 1261229 B.C.
accessnewswire.com
- 1 month ago
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
accessnewswire.com
- 1 month ago
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P.
accessnewswire.com
- 1 month ago
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment.
seekingalpha.com
- 1 month ago
8. Profile
Summary
Bausch Health Companies Inc. BHC
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 1.94 B
Dividend Yield
0.00%
Description
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Contact
2150 St. ElzEar Boulevard West, Laval, QC, H7L 4A8
https://www.bauschhealth.com
IPO
Date
March 29, 1994
Employees
20700
Officers
Dr. Jonathan Sadeh M.D., M.Sc.
Executive Vice President, Chief Medical Officer and Head of R&D
Mr. William N. Woodfield
Senior Vice President & Treasurer
Mr. Thomas J. Appio
Chief Executive Officer & Director